BioStock: CombiGene signs agreement and insiders buy shares

Today, CombiGene successfully completed the first large-scale production of its drug candidate CG01, which is being developed for the treatment of drug-resistant focal epilepsy. An agreement was also signed during the week with British Neurochase to optimise the injection strategy and maximise the safety and effect of CG01, which is to be injected directly into human brain tissue. In what appears to be a reaction to the news flow, the company was able to announce yesterday that both major shareholders, board members and former board members intend to subscribe for shares in CombiGene’s warrants, whose subscription period ends on 30 November.

Read the full article about CombiGene at biostock.se:

https://www.biostock.se/en/combigene-signs-agreement-and-insiders-buy-shares/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/